People · Operator
Named in public records as an officer, director or promoter · active 2022–2022 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Equilibre BioPharmaceuticals Corp. | — | Pharmaceuticals | Series B | $47.7M | $79.7M | 2022 |
Peter M. Simon at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Peter M. Simon on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| David Friedman | 1 | 9 |
| Joel Marcus | 1 | 9 |
| Peter Simon | 1 | 6 |
| Philip Barach | 1 | 3 |
| Steven Gordon | 1 | 3 |
| Steven N Gordon | 1 | 3 |
| David A. Friedman | 1 | 2 |
| Samuel Waksal | 1 | 2 |
| Philip A. Barach | 1 | 1 |
| Christopher M. Thorn | 1 | 1 |
| Christina A. Ramirez | 1 | 1 |
| Francois A. Maisonrouge | 1 | 1 |
| Francois Maisonrouge | 1 | 1 |
| Sam Waksal | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.